New drug aims to harness immune system against pancreatic cancer

NCT ID NCT07024615

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental drug called ASP2138 in 25 adults with resectable pancreatic cancer whose tumors have a specific protein (CLDN18.2). Participants receive ASP2138 two weeks before surgery, then standard chemotherapy after surgery. The main goal is to check safety and side effects, not yet to prove the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP2138 (an experimental drug that helps immune cells attack tumors with CLDN18.2 protein)
What this could lead to: If it works, this could point toward a new treatment option for people with resectable pancreatic cancer whose tumors have a specific protein.
What could go wrong: This is a very early (Phase 1) and small (25 people) trial focused on safety, not effectiveness. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke University Medical Center - Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.